Similar Posts
Drugmakers look to a more flexible Pharma 4.0
FDA Guidance for Data Integrity and Compliance
US FDA Quality Metrics Guidelines Update
FDA - Q8, Q9, & Q10 Questions and Answers
Who owns the BOM (Bill of Materials) in an FDA audit?
Share
  • Not Answered

Is the FDA stunting growth at Indian drugmakers?

To the community members in India. 

A recent article in In-PharmaTechnologist cited greater regulatory action by the US FDA on Indian manufacturers

http://www.in-pharmatechnologist.com/Regulatory-Safety/Tighter-GMPs-a-significant-risk-for-Indian-drugmakers-CARE?nocount

Have those of you in India seen these effects?  How are your companies responding?

Chris Amstutz

This is the official online community site of the Emerson Exchange, a forum for the free exchange of non-proprietary information among the global user community of all Emerson's products and services. Our goal is to improve the efficiency and use of automation systems and solutions employed at members’ facilities by sharing our knowledge, experiences, and application information.

Community Guidelines | Legal Information | Privacy Policy | Contact Community Manager

Website translation provided by Website Translator

© 2015-2026 Emerson Exchange. All rights reserved.